Stockscreener 앱 받기
1.01%
시간 외 거래:
Amgen Inc 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy? - Yahoo Finance
Amgen Faces 340B Lawsuit Spotlighting Drug Pricing And Investor Risks - simplywall.st
Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies - MSN
Amgen (NASDAQ:AMGN) Hits New 1-Year HighHere's Why - MarketBeat
Amgen: A Buy In 2026 On Exciting MariTide ObesityT2D Potential (NASDAQ:AMGN) - Seeking Alpha
Amgen stock hits 52-week high at $346.41 - Investing.com
Sagebrush sues Amgen over 340B program row - The Pharma Letter
Rakuten Investment Management Inc. Purchases Shares of 27,258 Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Downgraded by Bernstein on Market Challenges - GuruFocus
Ember LifeSciences Taps Former Amgen Exec as CFO - Contract Pharma
Amgen downgraded at Bernstein on 2026 outlook - MSN
Cell and Gene Therapy Market Innovations and Key Players: Amgen - openPR.com
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative - Investing.com
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - The AI Journal
Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies - Finviz
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52 - Yahoo Finance
AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout - Chartmill
Arkadios Wealth Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Red Biotechnology Market Is Going to Boom 20262023 |Amgen Inc., Gilead Sciences, Inc., Biogen - openPR.com
Lobbying Update: $3,550,000 of AMGEN INC lobbying was just disclosed - Quiver Quantitative
Sagebrush Health Sues Amgen for Over $7 Million in Damages - Intellectia AI
Amgen (AMGN) Downgraded by Bernstein, Price Target Unchanged | A - GuruFocus
Bernstein downgrades Amgen as 2026 lacks near-term catalysts - Investing.com
Sanford C. Bernstein Downgrades Amgen (NASDAQ:AMGN) to Market Perform - MarketBeat
Seizert Capital Partners LLC Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Pacific Heights Asset Management LLC Has $23.99 Million Holdings in Amgen Inc. $AMGN - MarketBeat
UPS building massive $6 million cooler - The Business Journals
40 Under 40: Melissa Wagner, Amgen - Medical Marketing and Media
A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum - Yahoo Finance
Amgen stock hits pause on MLK Day — what to watch before AMGN returns Tuesday - TechStock²
Tradewinds LLC. Makes New $988,000 Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 93% Above Its Share Price - 富途资讯
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - Yahoo Finance
Royal Fund Management LLC Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
3,785 Shares in Amgen Inc. $AMGN Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Allstate Corp Has $5.54 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
DISCO Oncology Pact And MariTide Obesity Data Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
Sequoia Financial Advisors LLC Has $45.33 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company - Yahoo Finance
Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year! - Smartkarma
WoodTrust Financial Corp Sells 588,232 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Cut by QRG Capital Management Inc. - MarketBeat
Pinnacle Financial Partners Inc Has $13.66 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation As Shares Track Close To Analyst Targets - simplywall.st
Lobbying Update: $60,000 of AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. lobbying was just disclosed - Quiver Quantitative
Wright Investors Service Inc. Has $2.76 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen’s Stock Under the Microscope: Modest Drop, Rising Expectations and Fresh Biotech Catalysts - AD HOC NEWS
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Amgen (AMGN) Still Attractive After A 26% One Year Share Price Gain - simplywall.st
Amgen Teases Phase 2 Results for MariTide, Its Weight-Loss Drug - Barron's
Amgen Inc. (AMGN): A Bull Case Theory - Finviz
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next - TipRanks
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide - TipRanks
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - sharewise.com
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data - Yahoo Finance
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc. - MarketBeat
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
1.57%
1.74%
자본화:
|
볼륨(24시간):